Authors
Latest:
Dr Townsend on the Genetic Evolutionary Trajectory of Prostate CancerJeffrey P. Townsend, PhD, on a novel approach to comprehending the evolutionary trajectory of prostate cancer through genetic profiling.
Latest:
Dr. Shi on the Rationale to Evaluate a Tumor-Treating Fields Therapy–Based Combination in GlioblastomaWenyin Shi, MD, PhD, discusses the rationale to evaluate a tumor-treating fields therapy in combination with temozolomide and radiation therapy in glioblastoma.
Latest:
Dr Gallagher on Unmet Needs With ADCs in Breast CancerChristopher M. Gallagher, MD, discusses unmet needs surrounding the use of antibody-drug conjugates, as well as questions remaining with other approved agents in breast cancer.
Latest:
Practice Pearls for Toxicity Management With ADC Therapy in Breast and Gastric CancerShared practical advice on the management of toxicities associated with antibody drug conjugate therapy in both the breast cancer and GI cancer settings.
Latest:
Dr Mohty on the Promise of Elranatamab in Relapsed/Refractory Multiple MyelomaMohamad Mohty, MD, PhD, discusses the promise of the phase 2 MagnetisMM-3 trial in patients with relapsed/refractory multiple myeloma, which is investigating elranatamab monotherapy in this patient population.
Latest:
Overcoming Racial Inequality in Epithelial Ovarian Cancer ResearchDanja Sarink, PhD, discusses the importance of studying race and ethnicity in epithelial ovarian cancer research.
Latest:
Dr Naik on the Evolving Role of Bispecific Antibodies in Multiple MyelomaSeema G. Naik, MD, discusses the evolving role of bispecific antibodies in hematologic malignancies.
Latest:
Dr. Hewitt on Considerations for Conservation Vs Mastectomy in Breast CancerKelly Hewitt, MD, discusses treatment considerations for breast conservation vs mastectomy in breast cancer.
Latest:
Epidemiology, Treatment of an Aging Inflammatory Bowel Disease PopulationAdam S. Faye, MD, of NYU Grossman School of Medicine, discusses the epidemiology and treatment for aging patients with inflammatory bowel disease.
Latest:
Dr. Reid on Remaining Challenges Regarding the Management of Immune-Related AEsPankti Reid, MD, MPH, discusses remaining challenges regarding the management of immune-related adverse effects.
Latest:
Virtual Surveillance Visits with Symptom, Serum CA-125 Review May Offer Alternative for Ovarian Cancer Recurrence Detection.In patients with ovarian cancer and pretreatment elevated CA-125 who achieved remission after frontline therapy, most recurrences are detected by rising CA-125 levels or symptoms.
Latest:
Dr. Dhir on Ongoing Research Efforts in Epithelioid and Synovial SarcomaAditi Dhir, MD, discusses ongoing efforts in epithelioid and synovial sarcoma.
Latest:
Dr. Tan on the Potential of Elacestrant in the EMERALD Trial in ER+ Breast CancerAntoinette R. Tan, MD, MHSc, discusses the potential of the oral selective estrogen receptor degrader elacestrant being investigated in the phase 3 EMERALD trial in estrogen receptor–positive breast cancer.
Latest:
Treatment Sequencing and Future of GVHDDr Nelson J. Chao reviews treatment sequencing and speculates on the future of the GVHD treatment landscape.
Latest:
Dr Möller on Gender Biases in OncologyMecker G. Möller, MD, discusses the importance of addressing gender biases in oncology.
Latest:
Baptist Health Miami Cancer Institute Celebrates 1000th Patient Treated Using Gamma KnifeBaptist Health Miami Cancer Institute treated its 1000th patient using Gamma Knife radiosurgery, an incisionless radiation therapy that precisely targets a tumor, importantly minimizing damage to otherwise healthy brain tissue.
Latest:
Dr Khan on Optimizing Local Therapy Using MRI and a 12-Gene Expression Assay in DCISSeema A. Khan, MD, discusses 5-year clinical outcomes from the ECOG-ACRIN E4112 trial, which is evaluating the use of MRI and a 12-gene expression assay to optimize local therapy for patients with ductal carcinoma in situ.
Latest:
Dr Fashemi on the Effect of Entinostat on Olaparib Responsiveness in Mouse HRP Ovarian Cancer ModelsBisiayo Fashemi, PhD, discusses how the addition of entinostat to olaparib could help combat PARP inhibitor-resistance in homologous recombination proficient ovarian cancer, as well as the clinical significance of utilizing mouse organoid models to investigate such strategies.
Latest:
Dr Conlin on Targeting CNS Metastases in the Treatment of Breast CancerAlison K. Conlin, MD, discusses the importance of targeting central nervous system metastases in the treatment of patients with breast cancer, highlighting ongoing treatment investigations for this population.
Latest:
What If We Could Eliminate a Major Gastric Cancer Risk Factor?A study by Sylvester Comprehensive Cancer Center assessed the outcomes of a community-based effort to test for and eradicate H. pylori, a major risk factor for gastric cancer.
Latest:
Dr. Nath on the Interim Results of the SIERRA Trial in Relapsed/Refractory AMLRajneesh Nath, MD, discusses the interim results of the phase 3 SIERRA trial in patients with relapsed/refractory acute myeloid leukemia.
Latest:
Future Directions in the Management of Immune ThrombocytopeniaExpert panelists reflect on the advent of newer therapies in immune thrombocytopenia and look toward future evolutions in care.
Latest:
Key Takeaways on Updates in Bladder CancerElizabeth Plimack, MD, MS, FASCO, recaps the discussion with key takeaways on recent updates in bladder cancer.
Latest:
Dr. Bhat on ELEVATE-TN Results in Treatment-Naïve CLLSeema A. Bhat, MD, discusses the results of the phase 3 ELEVATE-TN trial in patients with treatment-naïve CLL.
Latest:
Dr. Bonvalot on the Long-Term Safety of NBTXR3 Plus Radiotherapy in Locally Advanced Soft Tissue SarcomaSylvie Bonvalot, MD, PhD, HDR, discusses the long-term safety of NBTXR3 plus radiotherapy in patients with locally advanced soft tissue sarcoma who were treated in the phase 2/3 Act.In.Sarc trial.
Latest:
Dr. Weinberg on Treating Patients with NTRK Fusions in NSCLCFrank Weinberg, MD, PhD, discusses the treatment options in non–small cell lung cancer harboring NTRK fusions.
Latest:
Exploring Real-World Evidence Presented at ATA 2023Medical professionals discuss the recently published real-world evidence presented at the American Thyroid Association 2023 Conference.
Latest:
Dr. Karim on the Rationale for the CheckMate-73L Trial With Ipilimumab/Nivolumab in NSCLCNagla Abdel Karim, MD, discusses the rationale for the phase 3 CheckMate-73L trial that is being conducted in patients with stage III non–small cell lung cancer that is unable or not planned to be removed by surgery.
